Physician profile
Frederick B Lee
NPI 1962448266
$7,282.87
in general payments reported to CMS, 2019-2025
27 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $415 · 2021: $1,243 · 2022: $1,264 · 2023: $1,110 · 2024: $931 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577 · Education: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,576.77 |
| Education | $517.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,671.10 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Astrazeneca Pharmaceuticals Lp | $1,064.86 | 2019-2025 | Lokelma, Farxiga |
| Opko Pharmaceuticals, LLC | $741.49 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $655.83 | 2021-2025 | |
| Akebia Therapeutics INC | $654.38 | 2019-2024 | Auryxia, Vafseo |
| Vifor Pharma, INC. | $536.56 | 2019-2024 | Korsuva, Veltassa |
| Amgen INC. | $422.45 | 2019-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $368.07 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $236.24 | 2021-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $167.95 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $151.21 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.57 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $61.99 | 2022-2025 | Filspari |
| Novo Nordisk INC | $51.35 | 2025 | Rybelsus, Ozempic, Wegovy |
| Ultragenyx Pharmaceutical INC. | $46.20 | 2023-2024 | Crysvita |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $44.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $41.80 | 2023-2024 | |
| Shire North American Group INC | $40.53 | 2019 | |
| Glaxosmithkline, LLC. | $38.91 | 2022-2023 | Jesduvroq |
| Medtronic, INC. | $38.28 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $37.90 | 2022 | |
| Kyowa Kirin, INC. | $23.60 | 2025 | |
| Shield Therapeutics INC | $22.24 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.77 | 2019 | |
| Ardelyx, INC. | $18.01 | 2025 | Ibsrela |
| Horizon Therapeutics Plc | $16.13 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.